U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry RACEMIC
Molecular Formula C18H23NO3S
Molecular Weight 333.445
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CIGLITAZONE

SMILES

CC3(COC1=CC=C(CC2SC(=O)NC2=O)C=C1)CCCCC3

InChI

InChIKey=YZFWTZACSRHJQD-UHFFFAOYSA-N
InChI=1S/C18H23NO3S/c1-18(9-3-2-4-10-18)12-22-14-7-5-13(6-8-14)11-15-16(20)19-17(21)23-15/h5-8,15H,2-4,9-12H2,1H3,(H,19,20,21)

HIDE SMILES / InChI

Description

Ciglitazone, 5-[4-(1-methylcyclohexylmethoxy) benzyl]-thiazolidine-2,4-dione, is a hypoglycemic agent and a thiazolidenedione derivative. Ciglitazone binds to the PPAR gamma receptor and possesses agonist activity. This drug was in clinical trials in Japan for the treatment Diabetes mellitus, but that study has been discontinued. Ciglitazone was able to decrease the production of vascular endothelial growth factor (VEGF) in an in vitro human granulosa cell model. That result together with the pivotal role of VEGF in ovarian hyperstimulation syndrome suggests that ciglitazone may have a high potential as a therapeutic agent.

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown
Primary
Unknown

Cmax

ValueDoseCo-administeredAnalytePopulation
4.5 μg/mL
125 mg single, oral
CIGLITAZONE plasma
Canis lupus
3 μg/mL
125 mg single, oral
CIGLITAZONE plasma
Canis lupus

AUC

ValueDoseCo-administeredAnalytePopulation
138 μg × h/mL
125 mg single, oral
CIGLITAZONE plasma
Canis lupus
93 μg × h/mL
125 mg single, oral
CIGLITAZONE plasma
Canis lupus

PubMed

Sample Use Guides

In Vivo Use Guide
for Diabetes mellitus in Japan
Route of Administration: Oral
In Vitro Use Guide
Human middle ear epithelial cell lines (HMEECs) with or without ciglitazone pre-treatment were exposed to cigarette smoke solution (CSS) in order to induce the inflammatory response. The suppressive effect of inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-α) and cyclooxygenase-2(COX-2), were evaluated using real-time polymerase chain reaction and Western blotting. Stimulation with CSS at 40 μg/ml for 6 h resulted in a 4.1-fold increase in the expression of TNF-α mRNA in the HMEECs. CSS-induced up-regulation of TNF-α mRNA was decreased by more than 2.8-fold in cells pre-treated with ciglitazone. The up-regulation of COX-2 mRNA and increased COX-2 protein expression induced by CSS were also inhibited by more than 3.7-fold with ciglitazone pre-treatment.